spironolactone has been researched along with Fibromyalgia in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Fibromyalgia: A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases." | 7.01 | High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). ( Böhm, R; Cascorbi, I; Gleim, M; Gruenewald, M; Herdegen, T; Ohnesorge, H; Westermann, P, 2021) |
| "Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases." | 3.01 | High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). ( Böhm, R; Cascorbi, I; Gleim, M; Gruenewald, M; Herdegen, T; Ohnesorge, H; Westermann, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, R | 1 |
| Westermann, P | 1 |
| Gleim, M | 1 |
| Cascorbi, I | 1 |
| Gruenewald, M | 1 |
| Herdegen, T | 1 |
| Ohnesorge, H | 1 |
1 trial available for spironolactone and Fibromyalgia
| Article | Year |
|---|---|
High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT).
Topics: Adult; Double-Blind Method; Female; Fibromyalgia; Humans; Pain; Spironolactone; Treatment Outcome | 2021 |